Catalyst Pharmaceuticals, Inc

(NASDAQ:CPRX)

Latest On Catalyst Pharmaceuticals, Inc (CPRX):

Date/Time Type Description Signal Details
2023-05-11 18:16 ESTNewsCatalyst Pharmaceuticals (CPRX) Q1 2023 Earnings Call TranscriptN/A
2023-05-11 03:27 ESTNewsCatalyst Pharmaceuticals beats Q1 top and bottom line estimates; reaffirms FY23 outlookN/A
2023-05-10 01:27 ESTNewsCatalyst Pharmaceuticals Q1 2023 Earnings PreviewN/A
2023-04-19 09:17 ESTNewsCatalyst Pharmaceuticals: Fixing Its Misnomer Is No Easy TaskN/A
2023-04-18 21:51 ESTNewsCatalyst Pharma And Teva's ANDA Challenge: Firdapse Hangs By A ThreadN/A
2023-04-17 20:10 ESTNewsCatalyst Pharmaceuticals: A One-Hit Wonder With UpsideN/A
2023-03-31 18:52 ESTNewsDefense Is The Best Offense: 3 Stocks To BuyN/A
2023-03-16 16:11 ESTNewsCatalyst Pharmaceuticals, Inc. (CPRX) Q4 2022 Earnings Call TranscriptN/A
2023-03-16 01:07 ESTNewsCatalyst Pharmaceuticals Non-GAAP EPS of $0.31 beats by $0.11, revenue of $60.76M beats by $0.12MN/A
2023-03-14 18:44 ESTNewsCatalyst Pharmaceuticals Q4 2022 Earnings PreviewN/A
2023-02-07 17:49 ESTNewsCatalyst Pharmaceuticals jumps 2% on prelim Q4 and FY 2022 reportsN/A
2023-02-01 02:51 ESTNewsCatalyst Pharmaceuticals: Stable Upside Potential Amid Patent Infringement ConcernsN/A
2023-01-31 14:06 ESTNewsCatalyst Pharmaceuticals: Teva's Patent Challenge Of Firdapse Could Spell The End For This Cash CowN/A
2023-01-31 01:26 ESTNewsCatalyst Pharmaceuticals: The Firdapse Complexity Does Not EndN/A
2023-01-23 13:52 ESTNewsCatalyst stock slumps ~20% as Teva seeks FDA approval of generic FirdapseN/A
2022-12-20 09:43 ESTNewsCatalyst Pharma gains U.S. rights to Eisai epilepsy drug FycompaN/A
2022-11-22 18:17 ESTNewsCatalyst Pharma hits 52-week high amid acquisition hopesN/A
2022-11-15 17:12 ESTNewsCatalyst Pharmaceuticals: Undervalued And Likely To OutperformN/A
2022-11-10 15:03 ESTNewsCatalyst Pharmaceuticals, Inc. (CPRX) Q3 2022 Earnings Call TranscriptN/A
2022-11-09 22:21 ESTNewsCatalyst Pharmaceuticals Non-GAAP EPS of $0.26 beats by $0.07, revenue of $57.24M beats by $3.55MN/A
2022-11-09 04:06 ESTNewsCatalyst Pharmaceuticals Q3 2022 Earnings PreviewN/A
2022-09-17 01:33 ESTNewsCatalyst Pharma falls after a series of insider salesN/A
2022-09-14 20:33 ESTNewsCatalyst Pharmaceuticals Ramp May Be Over For NowN/A
2022-09-13 08:44 ESTNewsCatalyst Pharmaceuticals gains 9% on SmallCap 600 additionN/A
2022-09-13 08:44 ESTNewsHot Stocks: ORCL gains on earnings, WKHS jumps on patent, CPRX rises, TSN dips on downgradeN/A
2022-08-24 18:50 ESTNewsCatalyst Pharma ends momentum as Roth downgradesN/A
2022-08-12 17:09 ESTNewsCatalyst Pharmaceuticals: Performing Above ExpectationsN/A
2022-08-10 14:35 ESTNewsCatalyst stock rises 20% as Firdapse revenue grows with Ruzurgi woes settledN/A
2022-08-10 14:35 ESTNewsCatalyst Pharmaceuticals, Inc. (CPRX) CEO Patrick McEnany on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-09 21:44 ESTNewsCatalyst Pharmaceuticals Non-GAAP EPS of $0.28 beats by $0.11, revenue of $53.11M beats by $4.03M, re-affirms FY22 guidanceN/A
2022-08-09 00:34 ESTNewsCatalyst Pharmaceuticals Q2 2022 Earnings PreviewN/A
2022-07-12 08:00 ESTNewsCatalyst settles patent lawsuit for autoimmune disorder drug Firdapse with JacobusN/A
2022-05-27 02:25 ESTNewsCatalyst Pharmaceuticals (CPRX) Investor Presentation - SlideshowN/A
2022-05-13 09:02 ESTNewsCatalyst Pharmaceuticals, Inc.'s (CPRX) CEO Patrick McEnany on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-11 21:27 ESTNewsCatalyst Pharmaceuticals, Inc. (CPRX) CEO Patrick McEnany on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-11 21:27 ESTNewsCatalyst Pharmaceuticals Q1 earnings rise Y/Y; reaffirms FY22 revenue outlookN/A
2022-05-11 02:00 ESTNewsCatalyst Pharmaceuticals Non-GAAP EPS of $0.18, revenue of $43.09MN/A
2022-05-11 02:00 ESTNewsCatalyst: Upside Outlier - In Search Of A CatalystN/A
2022-05-10 04:06 ESTNewsCatalyst Pharmaceuticals Q1 2022 Earnings PreviewN/A
2022-03-20 01:07 ESTNewsCatalyst Pharmaceuticals, Inc.'s (CPRX) CEO Patrick McEnany on Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-18 15:46 ESTNewsCatalyst Pharmaceuticals, Inc. (CPRX) CEO Patrick McEnany on Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-17 05:23 ESTNewsCatalyst Pharmaceuticals GAAP EPS of $0.09 misses by $0.03, revenue of $38.31M beats by $0.13MN/A
2022-03-17 05:23 ESTNewsCatalyst Pharmaceuticals' quarterly net gain narrows though revenue increasesN/A
2022-03-15 20:17 ESTNewsCatalyst Pharmaceuticals Q4 2021 Earnings PreviewN/A
2022-03-02 15:22 ESTNewsCatalyst to get 3 more US patents for rare autoimmune disorder drug FirdapseN/A
2022-02-07 19:57 ESTNewsCatalyst Pharmaceuticals expects Q4 revenues to rise 24% Y/Y; provides 2022 outlookN/A
2022-02-04 02:27 ESTNewsCatalyst gets court's favorable judgement in FDA lawsuit over rival drug approvalN/A
2022-01-28 22:32 ESTNewsCatalyst says appeals court issued mandate in its favor in FDA lawsuitN/A
2022-01-20 17:43 ESTNewsCatalyst: A Classic Case Of Watch That BasketN/A
2021-11-15 22:59 ESTNewsCatalyst Pharmaceuticals, Inc.'s (CPRX) CEO Patrick McEnany on Q3 2021 Results - Earnings Call TranscriptN/A

About Catalyst Pharmaceuticals, Inc (CPRX):

Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome. The company also develops Firdapse, which is in various clinical trials for the treatment of patients with congenital myasthenic syndrome, anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. Catalyst Pharmaceuticals, Inc. has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

CPRX Quotes by TradingView

See Advanced Chart

General

  • Name Catalyst Pharmaceuticals, Inc
  • Symbol CPRX
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 74
  • Fiscal Year EndDecember
  • IPO Date2006-11-08
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.catalystpharma.com
View More

Valuation

  • Trailing PE 5.93
  • Forward PE 12.25
  • Price/Sales (Trailing 12 Mt.) 3.77
  • Price/Book (Most Recent Quarter) 2.59
  • Enterprise Value Revenue 2.51
  • Enterprise Value EBITDA 7.08
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate $0.36
  • Next Year EPS Estimate $0.46
  • Next Quarter EPS Estimate $0.08
  • Profit Margin 63%
  • Operating Margin 35%
  • Return on Assets 17%
  • Return on Equity 58%
  • Revenue 119.07 million
  • Earnings Per Share $0.71
  • Revenue Per Share $1.15
  • Gross Profit 87.12 million
  • Quarterly Earnings Growth 3%
View More

Highlights

  • Market Capitalization 437.1 million
  • EBITDA 41.4 million
  • PE Ratio 35.27
  • Analyst Target Price $7.5
  • Book Value Per Share $1.63
View More

Share Statistics

  • Shares Outstanding 103.83 million
  • Shares Float 86.56 million
  • % Held by Insiders 698%
  • % Held by Institutions 69.58%
  • Shares Short 8.4 million
  • Shares Short Prior Month 9.21 million
  • Short Ratio 4.4
  • Short % of Float 9%
  • Short % of Shares Outstanding 8%
View More

Technicals

  • Beta 1.35
  • 52 Week High $5.19
  • 52 Week Low $2.88
  • 50 Day Moving Average 4.04
  • 200 Day Moving Average 3.53
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Catalyst Pharmaceuticals, Inc (CPRX) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Catalyst Pharmaceuticals, Inc (CPRX) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-16$31.01 million$0.11$0.0922.22%
2020-09-302020-11-09$N/A$0.41$0.10327.08%
2020-06-302020-08-10$N/A$0.09$0.095.88%
2020-03-312020-05-11$29.14 million$0.10$0.0915.34%
2019-12-312020-03-16$30.12 million$0.07$0.10-32.24%
2019-09-302019-11-12$30.9 million$0.13$0.1114.04%
2019-06-302019-08-07$28.84 million$0.10$0.03263.64%
2019-03-312019-05-10$12.45 million-$0.01-$0.1190.91%
2018-12-312019-03-18$500000-$0.14-$0.12-21.74%
2018-09-302018-11-07$N/A-$0.08-$0.08-6.67%
2018-06-302018-08-07$N/A-$0.06-$0.0820%
2018-03-312018-05-09$N/A-$0.06-$0.060%
2017-12-312018-03-14$N/A-$0.06-$0.060%
2017-09-302017-11-08$N/A-$0.05-$0.069.09%
2017-06-302017-08-09$N/A-$0.05-$0.0620%
2017-03-312017-05-10$N/A-$0.06-$0.060%
2016-12-312017-03-15$N/A-$0.05-$0.0725.93%
2016-09-302016-11-09$N/A-$0.05-$0.0616.67%
2016-06-302016-08-09$N/A-$0.06-$0.0820%
2016-03-312016-05-10$N/A-$0.07-$0.07-4.95%
2015-12-312016-03-15$N/A-$0.07-$0.07-3.7%
2015-09-302015-11-09$N/A-$0.05-$0.0728.57%
2015-06-302015-08-10$N/A-$0.06-$0.0714.29%
2015-03-312015-05-11$N/A-$0.07-$0.0922.22%
2014-12-312015-03-16$N/A-$0.05-$0.0728.57%
2014-09-302014-11-13$N/A-$0.07-$0.05-40%
2014-06-302014-08-13$N/A-$0.05-$0.0728.57%
2014-03-312014-05-15$N/A-$0.07-$0.06-16.67%
2013-12-312014-03-19$N/A-$0.02-$0.0771.43%
2013-09-302013-11-14$N/A-$0.13-$0.07-85.71%
2013-06-302013-08-15$N/A-$0.08-$0.06-33.33%
2013-03-312013-04-02$N/A-$0.04-$0.0955.56%
2012-09-302012-11-15$N/A-$0.08-$0.03-166.67%
2012-06-302012-08-15$N/A-$0.01-$0.0475%
2012-03-312012-04-02$N/A-$0.10-$0.06-66.67%
2011-09-302011-11-15$N/A-$0.05-$0.0728.57%
2011-06-302011-08-16$N/A-$0.06-$0.0825%
2011-03-312011-04-01$N/A-$0.04-$0.0742.86%
2010-12-312011-03-31$489000-$0.04-$0.0742.86%
2010-09-302010-11-16$N/A-$0.05-$0.0837.5%
2010-06-302010-08-13$N/A-$0.07-$0.070%
2010-03-312010-04-01$N/A-$0.06-$0.05-20%
2009-12-312010-03-31$N/A-$0.06-$0.05-20%
2009-09-302009-11-12$N/A-$0.09-$0.1010%
2009-06-302009-08-07$N/A-$0.13-$0.2035%
2009-03-312009-05-14$N/A-$0.22-$0.248.33%
2008-12-312009-03-26$N/A-$0.27-$0.23-17.39%
2008-09-302008-11-14$N/A-$0.22-$0.234.35%
2008-06-302008-08-15$N/A-$0.19
2008-03-312008-05-16$N/A-$0.13-$0.12-8.33%
2007-12-312008-03-26$N/A-$0.08-$0.07-14.29%
2007-09-302007-11-14$N/A-$0.06-$0.1662.5%
2007-06-302007-08-10$N/A-$0.10-$0.1428.57%
2007-03-312007-04-02$N/A-$0.07-$0.070%
2006-09-302006-12-16$N/A-$0.27

Catalyst Pharmaceuticals, Inc (CPRX) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Catalyst Pharmaceuticals, Inc (CPRX) Chart:

Catalyst Pharmaceuticals, Inc (CPRX) News:

Below you will find a list of latest news for Catalyst Pharmaceuticals, Inc (CPRX) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Catalyst Pharmaceuticals, Inc (CPRX) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-10-172.50CALL0 0674.33TRUE00
2025-10-1750CALL0 0448.88TRUE00
2025-10-177.50CALL0 0326.33TRUE00
2025-10-17100CALL0 0405.55TRUE00
2025-10-1712.50CALL0 0287.64TRUE00
2025-10-17150CALL0 0193.73TRUE00
2025-10-1717.52.9CALL0 1181.61TRUE00
2025-10-17201.5CALL0 91162.08TRUE00
2025-10-1722.50.41CALL28 65662.91FALSE-0.03-0.07
2025-10-17250.1CALL10 10567.11FALSE00
2025-10-17300.32CALL0 5131.97FALSE00
2025-10-172.50PUT0 00FALSE00
2025-10-1750PUT0 00FALSE00
2025-10-177.50PUT0 01329.91FALSE00
2025-10-17100PUT0 0955.47FALSE00
2025-10-1712.50PUT0 0731.68FALSE00
2025-10-17150.15PUT0 217206.23FALSE00
2025-10-1717.50.15PUT3 131476.74FALSE0.050.5
2025-10-17200.59PUT3 25562.64FALSE-0.06-0.09
2025-10-1722.51.6PUT0 2774.47TRUE00
2025-10-17254.32PUT0 188.23TRUE00
2025-10-17300PUT0 0219.8TRUE00
2025-11-212.50CALL0 0346.83TRUE00
2025-11-2150CALL0 0365.29TRUE00
2025-11-217.50CALL0 0147.86TRUE00
2025-11-21100CALL0 0195.85TRUE00
2025-11-2112.50CALL0 0132.08TRUE00
2025-11-21156.6CALL0 3123.54TRUE00
2025-11-2117.50CALL0 065.84TRUE00
2025-11-21202.45CALL56 5065.96TRUE-0.07-0.03
2025-11-2122.51.3CALL109 59663.31FALSE-0.11-0.08
2025-11-21250.4CALL9 5351.89FALSE-0.3-0.43
2025-11-21300.12CALL0 7116.73FALSE00
2025-11-21350CALL0 0272.51FALSE00
2025-11-21400CALL0 0295.71FALSE00
2025-11-212.50PUT0 0857.98FALSE00
2025-11-2150PUT0 0495.32FALSE00
2025-11-217.50PUT0 0668.84FALSE00
2025-11-21100PUT0 0272.77FALSE00
2025-11-2112.50PUT0 099.89FALSE00
2025-11-21150.3PUT0 5582.63FALSE00
2025-11-2117.50.93PUT0 1373.3FALSE00
2025-11-21201.6PUT0 8100.47FALSE00
2025-11-2122.52.75PUT116 159.87TRUE2.750
2025-11-21255.85PUT0 258.51TRUE00
2025-11-21307.6PUT0 2109.11TRUE00
2025-11-213512.6PUT0 20TRUE00
2025-11-21400PUT0 00TRUE00
2025-12-197.50CALL0 0205.34TRUE00
2025-12-19109.9CALL0 35153.95TRUE00
2025-12-1912.59.4CALL0 118117.97TRUE00
2025-12-19156.3CALL0 31270.75TRUE00
2025-12-1917.54.91CALL0 19238.67TRUE00
2025-12-19202.75CALL25 23759.81TRUE2.750
2025-12-1922.51.55CALL13 56156.34FALSE0.290.23
2025-12-19250.8CALL0 39757.32FALSE00
2025-12-19300.25CALL0 26456.8FALSE00
2025-12-19350.85CALL0 1787.19FALSE00
2025-12-197.50PUT0 0533.09FALSE00
2025-12-19100PUT0 0391.57FALSE00
2025-12-1912.50.1PUT0 892.31FALSE00
2025-12-19150.4PUT2 27468.96FALSE0.40
2025-12-1917.50.86PUT0 76965.95FALSE00
2025-12-19202.27PUT0 16962.64FALSE00
2025-12-1922.53.03PUT0 169753.31TRUE00
2025-12-19255.32PUT0 154353.01TRUE00
2025-12-193010.23PUT0 281.55TRUE00
2025-12-193515.51PUT0 095.71TRUE00
2026-03-207.50CALL0 0132.01TRUE00
2026-03-201012.39CALL0 11107.57TRUE00
2026-03-2012.59.01CALL0 2587.43TRUE00
2026-03-20156CALL0 1669.58TRUE00
2026-03-2017.55.2CALL3 3259.56TRUE5.20
2026-03-20203.69CALL0 22454.51TRUE00
2026-03-2022.52.5CALL223 24653.57FALSE-0.01-0
2026-03-20251.75CALL10 7453.89FALSE0.30.21
2026-03-20301.13CALL0 18950.96FALSE00
2026-03-20350.31CALL2 1651.4FALSE0.060.24
2026-03-207.50PUT0 0362.76FALSE00
2026-03-20100PUT0 0266.46FALSE00
2026-03-2012.51.3PUT0 5149.48FALSE00
2026-03-20150.38PUT0 1672.51FALSE00
2026-03-2017.51.4PUT5 256.05FALSE1.40
2026-03-20202.65PUT0 2471.05FALSE00
2026-03-2022.54.1PUT0 753.57TRUE00
2026-03-20250PUT0 056.95TRUE00
2026-03-203010.2PUT0 466.52TRUE00
2026-03-203515.7PUT0 070.5TRUE00

Latest CPRX Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST2$6.24
Jun 13, 2022 7:59 PM EST100$6.24
Jun 13, 2022 7:59 PM EST86$6.24
Jun 13, 2022 7:59 PM EST100$6.24
Jun 13, 2022 7:59 PM EST37$6.235

Catalyst Pharmaceuticals, Inc (CPRX) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-023Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169720000294/0001161697-20-000294-index.htm
2019-11-08UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1369568/000000000019015379/0000000000-19-015379-index.htm
2019-12-13UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1369568/000000000019016411/0000000000-19-016411-index.htm
2020-07-30UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1369568/000000000020006980/0000000000-20-006980-index.htm
2020-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1369568/000009375120000600/0000093751-20-000600-index.htm
2019-02-08SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1369568/000021545719006748/0000215457-19-006748-index.htm
2020-02-05SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1369568/000083423720004631/0000834237-20-004631-index.htm
2018-06-153Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000089924318016787/0000899243-18-016787-index.htm
2018-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1369568/000091957418001185/0000919574-18-001185-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1369568/000091957419001193/0000919574-19-001193-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1369568/000091957420001116/0000919574-20-001116-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1369568/000091957420001126/0000919574-20-001126-index.htm
2020-03-26SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1369568/000091957420002583/0000919574-20-002583-index.htm
2018-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1369568/000093041318000494/0000930413-18-000494-index.htm
2019-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1369568/000108514619000736/0001085146-19-000736-index.htm
2019-03-06SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1369568/000108514619001021/0001085146-19-001021-index.htm
2019-12-09SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1369568/000108514619003054/0001085146-19-003054-index.htm
2020-01-09SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1369568/000108514620000053/0001085146-20-000053-index.htm
2018-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1369568/000114420418007914/0001144204-18-007914-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1369568/000114420419007221/0001144204-19-007221-index.htm
2018-01-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169718000030/0001161697-18-000030-index.htm
2018-01-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169718000032/0001161697-18-000032-index.htm
2018-01-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169718000034/0001161697-18-000034-index.htm
2018-01-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169718000036/0001161697-18-000036-index.htm
2018-01-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169718000038/0001161697-18-000038-index.htm
2018-04-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169718000180/0001161697-18-000180-index.htm
2018-05-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169718000296/0001161697-18-000296-index.htm
2018-05-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169718000300/0001161697-18-000300-index.htm
2018-06-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169718000302/0001161697-18-000302-index.htm
2018-06-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169718000306/0001161697-18-000306-index.htm
2018-06-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169718000308/0001161697-18-000308-index.htm
2018-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169718000312/0001161697-18-000312-index.htm
2018-12-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169718000579/0001161697-18-000579-index.htm
2018-12-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169718000583/0001161697-18-000583-index.htm
2018-12-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169718000599/0001161697-18-000599-index.htm
2018-12-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169718000618/0001161697-18-000618-index.htm
2018-12-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169718000619/0001161697-18-000619-index.htm
2018-12-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169718000620/0001161697-18-000620-index.htm
2018-12-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169718000621/0001161697-18-000621-index.htm
2018-12-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169718000622/0001161697-18-000622-index.htm
2018-12-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169718000623/0001161697-18-000623-index.htm
2018-12-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169718000624/0001161697-18-000624-index.htm
2018-12-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169718000625/0001161697-18-000625-index.htm
2018-12-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169718000626/0001161697-18-000626-index.htm
2018-12-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169718000627/0001161697-18-000627-index.htm
2018-12-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169718000634/0001161697-18-000634-index.htm
2019-01-043Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169719000018/0001161697-19-000018-index.htm
2019-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169719000233/0001161697-19-000233-index.htm
2019-10-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169719000421/0001161697-19-000421-index.htm
2019-10-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169719000434/0001161697-19-000434-index.htm
2019-11-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169719000503/0001161697-19-000503-index.htm
2019-11-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169719000508/0001161697-19-000508-index.htm
2019-12-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169719000510/0001161697-19-000510-index.htm
2019-12-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169719000512/0001161697-19-000512-index.htm
2019-12-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169719000514/0001161697-19-000514-index.htm
2019-12-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169719000516/0001161697-19-000516-index.htm
2019-12-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169719000518/0001161697-19-000518-index.htm
2019-12-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169719000520/0001161697-19-000520-index.htm
2019-12-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169719000522/0001161697-19-000522-index.htm
2019-12-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169719000524/0001161697-19-000524-index.htm
2019-12-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169719000526/0001161697-19-000526-index.htm
2019-12-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169719000528/0001161697-19-000528-index.htm
2019-12-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169719000530/0001161697-19-000530-index.htm
2019-12-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169719000538/0001161697-19-000538-index.htm
2020-07-023Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169720000294/0001161697-20-000294-index.htm
2020-09-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169720000416/0001161697-20-000416-index.htm
2020-09-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1369568/000116169720000418/0001161697-20-000418-index.htm
2018-01-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312518005402/0001193125-18-005402-index.htm
2018-02-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312518039004/0001193125-18-039004-index.htm
2018-03-1410-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1369568/000119312518082292/0001193125-18-082292-index.htm
2018-03-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312518082373/0001193125-18-082373-index.htm
2018-03-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312518100672/0001193125-18-100672-index.htm
2018-04-17DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1369568/000119312518119932/0001193125-18-119932-index.htm
2018-04-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312518121919/0001193125-18-121919-index.htm
2018-05-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1369568/000119312518157513/0001193125-18-157513-index.htm
2018-05-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312518157634/0001193125-18-157634-index.htm
2018-05-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312518175523/0001193125-18-175523-index.htm
2018-05-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312518176046/0001193125-18-176046-index.htm
2018-05-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312518180466/0001193125-18-180466-index.htm
2018-06-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312518194622/0001193125-18-194622-index.htm
2018-06-29S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1369568/000119312518209752/0001193125-18-209752-index.htm
2018-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1369568/000119312518241075/0001193125-18-241075-index.htm
2018-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312518241295/0001193125-18-241295-index.htm
2018-08-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312518251807/0001193125-18-251807-index.htm
2018-11-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1369568/000119312518320889/0001193125-18-320889-index.htm
2018-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312518320996/0001193125-18-320996-index.htm
2018-11-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312518337245/0001193125-18-337245-index.htm
2018-12-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312518350053/0001193125-18-350053-index.htm
2018-12-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312518352167/0001193125-18-352167-index.htm
2018-12-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312518358175/0001193125-18-358175-index.htm
2019-03-1810-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1369568/000119312519078253/0001193125-19-078253-index.htm
2019-03-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312519078324/0001193125-19-078324-index.htm
2019-04-18DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1369568/000119312519111052/0001193125-19-111052-index.htm
2019-05-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1369568/000119312519144387/0001193125-19-144387-index.htm
2019-05-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312519144832/0001193125-19-144832-index.htm
2019-05-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312519157023/0001193125-19-157023-index.htm
2019-05-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312519159724/0001193125-19-159724-index.htm
2019-05-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312519161413/0001193125-19-161413-index.htm
2019-06-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312519171385/0001193125-19-171385-index.htm
2019-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1369568/000119312519215324/0001193125-19-215324-index.htm
2019-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312519215383/0001193125-19-215383-index.htm
2019-08-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312519235335/0001193125-19-235335-index.htm
2019-09-11424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1369568/000119312519243060/0001193125-19-243060-index.htm
2019-09-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312519244473/0001193125-19-244473-index.htm
2019-09-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312519253620/0001193125-19-253620-index.htm
2019-10-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312519278423/0001193125-19-278423-index.htm
2019-11-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1369568/000119312519290006/0001193125-19-290006-index.htm
2019-11-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312519290047/0001193125-19-290047-index.htm
2019-11-12CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1369568/000119312519290068/0001193125-19-290068-index.htm
2019-11-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312519302591/0001193125-19-302591-index.htm
2019-12-06CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1369568/000119312519308282/0001193125-19-308282-index.htm
2020-01-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312520001827/0001193125-20-001827-index.htm
2020-02-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312520024885/0001193125-20-024885-index.htm
2020-03-1610-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1369568/000119312520075048/0001193125-20-075048-index.htm
2020-03-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312520075118/0001193125-20-075118-index.htm
2020-04-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312520100911/0001193125-20-100911-index.htm
2020-04-2910-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1369568/000119312520126361/0001193125-20-126361-index.htm
2020-05-1110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1369568/000119312520139026/0001193125-20-139026-index.htm
2020-05-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312520139277/0001193125-20-139277-index.htm
2020-05-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312520141636/0001193125-20-141636-index.htm
2020-06-18PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1369568/000119312520172628/0001193125-20-172628-index.htm
2020-06-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312520180912/0001193125-20-180912-index.htm
2020-07-07DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1369568/000119312520188818/0001193125-20-188818-index.htm
2020-07-23S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1369568/000119312520197849/0001193125-20-197849-index.htm
2020-07-30CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1369568/000119312520203849/0001193125-20-203849-index.htm
2020-07-31424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1369568/000119312520206659/0001193125-20-206659-index.htm
2020-08-03DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1369568/000119312520208176/0001193125-20-208176-index.htm
2020-08-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312520208186/0001193125-20-208186-index.htm
2020-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312520211962/0001193125-20-211962-index.htm
2020-08-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1369568/000119312520214907/0001193125-20-214907-index.htm
2020-08-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312520215047/0001193125-20-215047-index.htm
2020-08-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312520216413/0001193125-20-216413-index.htm
2020-08-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312520225731/0001193125-20-225731-index.htm
2020-08-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312520227098/0001193125-20-227098-index.htm
2020-08-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312520231392/0001193125-20-231392-index.htm
2020-09-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312520244230/0001193125-20-244230-index.htm
2020-09-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312520258125/0001193125-20-258125-index.htm
2020-10-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312520264855/0001193125-20-264855-index.htm
2020-10-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1369568/000119312520271679/0001193125-20-271679-index.htm
2020-07-31EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1369568/999999999520001997/9999999995-20-001997-index.htm
2018-09-28CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1369568/999999999718008220/9999999997-18-008220-index.htm
2019-02-27CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1369568/999999999719000606/9999999997-19-000606-index.htm

Catalyst Pharmaceuticals, Inc (CPRX) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Catalyst Pharmaceuticals, Inc (CPRX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 698%
Institutional Ownership: 6958%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-11-21GARY INGENITOChief Medical OfficerSell100,000.004.50449,800.000.00https://www.sec.gov/Archives/edgar/data/1369568/000116169719000503/0001161697-19-000503-index.htm
2019-11-27GARY INGENITOChief Medical OfficerSell100,000.004.66466,000.000.00https://www.sec.gov/Archives/edgar/data/1369568/000116169719000508/0001161697-19-000508-index.htm
2019-12-05GARY INGENITOChief Medical OfficerSell150,000.004.82723,150.000.00https://www.sec.gov/Archives/edgar/data/1369568/000116169719000538/0001161697-19-000538-index.htm
2019-11-20GARY INGENITOChief Medical OfficerBuy100,000.000.7979,000.00100,000.00https://www.sec.gov/Archives/edgar/data/1369568/000116169719000503/0001161697-19-000503-index.htm
2019-11-27GARY INGENITOChief Medical OfficerBuy100,000.001.13113,000.00100,000.00https://www.sec.gov/Archives/edgar/data/1369568/000116169719000508/0001161697-19-000508-index.htm
2018-05-30DONALD A DENKHAUSDirectorBuy20,000.003.7575,000.00120,000.00https://www.sec.gov/Archives/edgar/data/1369568/000116169718000296/0001161697-18-000296-index.htm
2018-06-08DONALD A DENKHAUSDirectorBuy20,000.003.4168,200.00140,000.00https://www.sec.gov/Archives/edgar/data/1369568/000116169718000312/0001161697-18-000312-index.htm
2019-12-04GARY INGENITOChief Medical OfficerBuy150,000.002.53379,500.00150,000.00https://www.sec.gov/Archives/edgar/data/1369568/000116169719000538/0001161697-19-000538-index.htm
2018-12-14DONALD A DENKHAUSDirectorBuy60,000.002.48148,800.00200,000.00https://www.sec.gov/Archives/edgar/data/1369568/000116169718000583/0001161697-18-000583-index.htm
2018-12-27DONALD A DENKHAUSDirectorBuy25,000.001.9147,750.00225,000.00https://www.sec.gov/Archives/edgar/data/1369568/000116169718000634/0001161697-18-000634-index.htm
2018-04-03PATRICK J MCENANYPresident and CEOBuy20,000.002.2945,800.004,717,693.00https://www.sec.gov/Archives/edgar/data/1369568/000116169718000180/0001161697-18-000180-index.htm
2018-12-19PATRICK J MCENANYPresident and CEOBuy20,000.002.2444,800.004,737,693.00https://www.sec.gov/Archives/edgar/data/1369568/000116169718000599/0001161697-18-000599-index.htm
2019-06-11PATRICK J MCENANYPresident and CEOBuy25,000.003.2380,750.004,762,693.00https://www.sec.gov/Archives/edgar/data/1369568/000116169719000233/0001161697-19-000233-index.htm
2019-10-03PATRICK J MCENANYPresident and CEOBuy10,000.004.8948,900.004,772,693.00https://www.sec.gov/Archives/edgar/data/1369568/000116169719000421/0001161697-19-000421-index.htm
2020-09-30PATRICK J MCENANYPresident and CEOBuy15,000.002.9744,550.004,787,693.00https://www.sec.gov/Archives/edgar/data/1369568/000116169720000416/0001161697-20-000416-index.htm
2018-06-01Charles B O'KeeffeDirectorBuy5,000.003.7418,680.00518,376.00https://www.sec.gov/Archives/edgar/data/1369568/000116169718000302/0001161697-18-000302-index.htm
2018-06-07Charles B O'KeeffeDirectorBuy4,000.003.3113,222.00522,376.00https://www.sec.gov/Archives/edgar/data/1369568/000116169718000306/0001161697-18-000306-index.htm
2018-06-07Charles B O'KeeffeDirectorBuy1,000.003.353,352.30523,376.00https://www.sec.gov/Archives/edgar/data/1369568/000116169718000308/0001161697-18-000308-index.htm
2018-12-14Charles B O'KeeffeDirectorBuy20,000.002.5050,000.00543,376.00https://www.sec.gov/Archives/edgar/data/1369568/000116169718000579/0001161697-18-000579-index.htm
2019-10-11Charles B O'KeeffeDirectorBuy10,000.004.7046,950.00553,376.00https://www.sec.gov/Archives/edgar/data/1369568/000116169719000434/0001161697-19-000434-index.htm
2020-09-30Charles B O'KeeffeDirectorBuy7,000.002.9920,930.00560,376.00https://www.sec.gov/Archives/edgar/data/1369568/000116169720000418/0001161697-20-000418-index.htm